TORCH Publication, DTC Campaign Breathe Life Into Advair In Q1
This article was originally published in The Pink Sheet Daily
Executive Summary
New prescription trends for the long-acting beta agonist bronchodilator trended up following publication of study results in the New England Journal of Medicine, DTC ads.
You may also be interested in...
FDA Says GlaxoSmithKline’s Advair 500/50 “Not Approvable” For COPD
Agency questions efficacy of COPD treatment over lower strength; GSK tells “The Pink Sheet” DAILY that head-to-head trials were not conducted.
FDA Says GlaxoSmithKline’s Advair 500/50 “Not Approvable” For COPD
Agency questions efficacy of COPD treatment over lower strength; GSK tells “The Pink Sheet” DAILY that head-to-head trials were not conducted.
GSK Submits Advair sNDA Based on TORCH Data
Company is seeking expanded labeling and approval of an increased dosage for treatment of COPD.